WARREN, N.J. - PTC Therapeutics, Inc. (NASDAQ:PTCT) announced on Thursday that the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on its investigational drug PTC518 for Huntington's disease (HD) following encouraging interim results from a Phase 2 study.
The PIVOT-HD study's 12-month data showed that PTC518 led to a dose-dependent reduction in the mutant huntingtin (mHTT) protein levels in both blood and cerebrospinal fluid (CSF) among a cohort of HD patients. The study also observed a slowing in the progression of motor symptoms, with less worsening in the Total Motor Score (TMS) for patients treated with PTC518 compared to placebo.
PTC518's favorable safety and tolerability profile has remained consistent throughout the 12-month treatment period. Dr. Matthew B. Klein, CEO of PTC (NASDAQ:PTC) Therapeutics, expressed optimism about the drug's potential as a disease-modifying therapy for HD, a rare genetic disorder that progressively impairs nerve cells in the brain.
The interim analysis revealed that patients receiving 5mg and 10mg doses of PTC518 experienced a 22% and 43% reduction in blood mHTT levels, respectively. Similar reductions were also seen in the CSF. Motor symptom progression slowed more significantly for patients on the 10mg dose compared to those on the 5mg dose or placebo.
The FDA's decision to lift the partial clinical hold will allow PTC Therapeutics to proceed with further development of PTC518. The company plans to discuss these findings in a conference call and webcast.
PTC518 is part of PTC's splicing platform technology, designed to reduce the production of the toxic mHTT protein, which leads to neuron damage and disease progression. The orally bioavailable molecule is noted for its ability to cross the blood-brain barrier and its selective properties.
Huntington's disease affects the central nervous system, causing a wide range of symptoms including abnormal movements and cognitive decline. There is currently no cure for HD, and no drugs approved that can delay onset or slow progression, highlighting the significance of PTC518's development.
This news is based on a press release statement from PTC Therapeutics, Inc.
In other recent news, PTC Therapeutics has been the focus of several significant developments. Goldman Sachs (NYSE:GS) maintained a sell rating on the company's shares, but raised the price target from $18 to $32 following the European Commission's (EC) decision not to endorse the Committee for Medicinal Products for Human Use's (CHMP) second negative opinion on Translarna, a drug developed by PTC Therapeutics.
Jefferies also raised its price target for the stock, from $35 to $46, maintaining a buy rating after a re-evaluation of Translarna. Meanwhile, Raymond James upgraded PTC Therapeutics from underperform to market perform, reintroducing Translarna EU revenues into their financial model after the EC's decision.
The EC's decision to maintain Translarna's market presence in Europe under its existing authorization has been a major point of discussion. This decision followed a request for additional evaluation of the totality of evidence, including patient registry data and real-world evidence. The EC's stance has prompted PTC Therapeutics to pause its revenue guidance for the year until further clarity is provided.
PTC Therapeutics also announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for Upstaza, a gene therapy candidate for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency, and granted it Priority Review.
InvestingPro Insights
As PTC Therapeutics, Inc. (NASDAQ:PTCT) continues to make strides with its investigational drug PTC518 for Huntington's disease, it's important to consider the financial health and market sentiment surrounding the company. The recent FDA decision has potential implications for PTCT's stock performance and future prospects.
InvestingPro data shows that PTCT has a market capitalization of $2.73 billion, reflecting investor confidence in the company's pipeline and market position. Despite a challenging environment, PTCT has managed to achieve a revenue growth of 20.39% in the last twelve months as of Q1 2024, which is a testament to the company's resilience and strategic initiatives.
However, the company is not without its challenges. Analysts do not expect PTCT to be profitable this year, as indicated by a negative P/E ratio of -4.63 and an adjusted P/E ratio of -7.14. This is in line with the company's recent performance, which has not been profitable over the last twelve months. The revenue growth has seen a quarterly dip of -4.66% in Q1 2024, suggesting that the company may be facing headwinds in its financial performance.
On a positive note, PTCT has shown a strong return over the last three months, with a price total return of 20.7%. Additionally, the stock has experienced a large price uptick over the last six months, with a 31.73% return. This could be indicative of investor optimism following the company's advancements in drug development and the positive interim results from the PIVOT-HD study.
InvestingPro Tips for PTCT also highlight that the company does not pay a dividend to shareholders, which is not uncommon for biotechnology firms focused on reinvesting earnings into research and development.
For investors seeking more in-depth analysis and additional insights, InvestingPro offers a comprehensive set of tips for PTCT. There are currently 6 additional InvestingPro Tips available, which can be accessed by visiting https://www.investing.com/pro/PTCT. Don't forget to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, enriching your investment strategy with valuable information.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.